Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended June 30, 2026 financial results announced.
Oric Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 financial results announced
- Full results and management commentary available in Exhibit 99.1
- Investor focus: cash position, R&D spending, and clinical-program funding runway
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 Himalayas-1 initiated in approximately 600 mCRPC patients across 25 countries, materially advancing rinzimetostat toward registration
- Bayer supplying NUBEQA at no cost, preserving ORIC’s full global rights while reducing trial drug-supply expense
- $387.6M cash and investments expected to fund operations into 2H 2028, potentially through the first Phase 3 primary-endpoint readout
- Second-quarter net loss widened to $41.5M from $36.4M, with R&D expense rising to $36.3M as rinzimetostat development accelerated
- Enozertinib data expected in 2H 2026, including October 2026 ESMO presentation for first-line EGFR atypical mutations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oric Pharmaceuticals, Inc. 8-K filings
Get the next ORIC 8-K as it lands
Follow ORIC for push alerts, or ask the research agent what this filing means.